Conference Program 2015

December 3-4, 2015 (Amstel zaal)
VU Medical Center-Neuroscience Campus Amsterdam

VU Medical Center, Amstelzaal & Foyer, ZH 0 A 2
De Boelelaan 1117
1081 HV Amsterdam, The Netherlands

Day 1 (3 December 2015) – Scientific program

8:30 9:30 Registration, Meet & Greet
9:30 9:40 Opening and Welcome, Arjen Brussaard
Session 1 – Opening Lecture
Session headed by Arjen Brussaard
9:40 10:30 Opening lecture “Pathogenic protein seeding in Alzheimer disease and other neurodegenerative disorders, Mathias Jucker (University of Tubingen and German Center for Neurodegenerative Diseases)
10:30 11:00 coffee break
Session 2 – Preclinical research and disease mechanism
Session headed by Micha Wilhelmus
11:00 11:30 Invited lecture – Neurodegeneration and intracellular protein trafficking, Casper Hoogenraad (Utrecht University)
11:30 11:45 Selected lecture – The function of SERF in protein aggregation and Alzheimer disease, Esther Stroo (University of Groningen
11:45 12:00 Selected lecture – Towards the understanding of the disease mechanism of vanishing white matter, Truus Abbink (VUmc)
Session 3 – Pecha Kucha
Session headed Jeroen Hoozemans and Micha Wilhelmus
12:00 12:45 Short presentations of selected posters (7 min per presentation)
1) The molecular component of the neurodegenerative disorder spinocerebellar ataxia 19/22, Claudio Tiecher (University of Groningen)
2) Early-life stress modulates microglia function and Alzheimer’s Disease neuropathology in APPswe/PS1dE9 mice, Lianne Hoeijmakers (University of Amsterdam
3) The effect of acute BACE1 inhibition on early cognitive deficits in a mouse model of Aβ toxicity, Maarten Loos (Sylics, Amsterdam)
4) A new in vitro model for C9orf72 ALS/FTD, F.W. Riemslagh (Erasmus MC)
5) Improved CSF-based discrimination between Alzheimer patients and controls after correction for ventricular volumes, Linda J.C. van Waalwijk van Doorn (Radboud University Medical Center)
6) Gene-based analysis detects novel loci associated with frontotemporal dementia and its clinical subtypes, Aniket Mishra (VUmc)
12:45 14:30 Lunch and poster market
Session 4 – New biomarkers and therapy
Session headed by Jeroen Hoozemans
14:30 15:15 Invited lecture – The UPR as therapeutic target for neurodegeneration, Giovanna Mallucci (University of Cambridge)
15:15 15:30 Selected lecture – Cell-to-Cell Transmission of the Unfolded Protein Response and tau pathology, Wiep Scheper (VU University Medical Center)
15:30 15:45 Selected lecture – Role of TGF-βETA pathway in hereditary Cerebral Amyloid Angiopathy, Laure Grand Moursel (Leiden University Medical Center)
15:45 16:00 Selected lecture – Lower cerebral blood flow is related to more severe cognitive impairment in patients with dementia due to AD, A.E. Leeuwis (VUmc)
16:00 16:30 Refreshment break
Session 5 – Towards Industry-Academia collaboration
Session headed by Bonno N. Bouma, Emeritus Professor, UMC Utrecht
16:30 16:50 Models for drug discovery, Armand Tepper (Crossbeta Biosciences)
16:50 17:10 Target discovery in the synapse, Guus Smit (VU university)
17:10 17:45 CNS drug development, Chris Parsons (Merz Pharmaceuticals)
17:45 20:00 Reception sponsored by Crossbeta Biosciences

Day 2 (4 December 2015) – Scientific & Industry Alliance Program

8:45  Welcome and introduction, Arjen Brussaard & Wiesje van der Flier

Session 6 – Scientific program (Memorabel projects[1])
Session headed by Wiesje van der Flier
9:00 9:15 Wiesje van der Flier (VUmc) – ABIDE: Alzheimer’s Biomarkers in Daily Practice
9:15 9:30 Femke Bouwman (VUmc) – PAGE-AD: Pathological substrate of clinical variability in AD
9:30 9:45 Marcel Verbeek (Radboud UMC) – CAVIA: Cerebral Amyloid Angiopathy: Vascular Imaging and fluid markers of Amyloid deposition
9:45 10:00 Charlotte Teunissen (VUmc) – PRODIA: Development of biomarkers enabling early and accurate differential diagnosis of dementia
10:00 10:15 Kerensa Broersen (UTwente) – Exploring the potential of multi-target treatment for Alzheimer’s disease: towards an integrated and transdisciplinary approach
10:15 10:30 Pilar Martinez (MUMC) – Sphingolipids: a novel target in the treatment of Alzheimer Disease?
10:30 11:00 Refreshment break
Session 7 – Towards interventions
Session headed by Arjen Brussaard
11:00 11:30 Disease interventions, Stephan Schilling (Probiodrug)
“Developing anti pGlu-Ab therapies – a differentiated Ab approach to treat Alzheimer’s Disease”.
11:30 12:00 Disease interventions, Peter Lansbury (Lysosomal Therapeutics)
“a divide and conquer approach to Parkinson’s disease”
12:00 12:30 Perspective on industry academia collaboration, John Allam (EIP Pharma)
“Translational Medicine Success: The Importance of Committed and Enduring Acadamic-Industry Collaboration”
12:30 13:00 Clinical trials, Philip Scheltens (Alzheimer Center Amsterdam)
“50 ways to improve your clinical trial in AD”
13:00 14:00 Lunch, partnering and refreshment break
Session 8 – Industry meets academia and affiliates
14:00 – 16:15 Round Table discussions (3 sessions of 40 minutes)
Round Table 1: Target Validation (Jeroen Hoozemans & Annemieke Rozemuller)
Round Table 2: Disease pathways (Pim van Nierop & Arjen Brussaard)
Round Table 3: iPS & Cellomics (Ruud Toonen & Ronald van Kesteren)
Round Table 4: PET and MRI imaging (Bart van Berckel & Hugo Vrenken/Mike Wattjes)
Round Table 5: Cognitive & functional measurements (Wiesje van der Flier & Roos Jutten)
Round Table 6: Clinical trial expertise & guidance (Philip Scheltens & Niels Prins)
16:15 – 17:00 Round up and panel discussion (with Probiodrug, Lysosomal Thx, EIPharma & NCA officials)
17:00 18:00 Drinks sponsored by Neuroscience Campus Amsterdam

>Download Program (pdf)

[1] Memorabel Projects = Scientific project supported by the Dutch Research Counicel (NOW/ZONMW) on Neurodegeration, involving industrial partnerships